Cell therapy wins FDA recommendation

The US FDA’s recommended approval of Novartis’ CAR-T cell therapy pushes the product closer to being the first treatment of its kind available on the market.Bruno Strigini, CEO, Novartis Oncology said: "The panel's unanimous recommendation in favor of CTL019 moves us closer to potentially delivering the first-ever commercially approved CAR-T cell therapy to patients in need,""We're very proud to be expanding new frontiers in cancer treatment by advancing immunocellular therapy for children and y... To continue reading this story Click Here